Montgomery Manor Convalescent Hospital Memorial Fund Inc
- Assets
- $34.4k
- Revenue
- $454.3k
- Investments
- $0.0
- Employees
- 7
- Location
- Santa Rosa, CA
- Founding
- 02/1985
- Data as of
- 12/2018
- EIN
- 68-0041590
Organization Overview
Montgomery Manor Convalescent Hospital Memorial Fund Inc is located in Santa Rosa, CA. The organization was established in 1985. According to its NTEE Classification (E91) the organization is classified as: Nursing Facilities, under the broad grouping of Health Care and related organizations. As of 12/2018, Montgomery Manor Convalescent Hospital Memorial Fund Inc employed 7 individuals. This organization is an independent organization and not affiliated with a larger national or regional group of organizations. Montgomery Manor Convalescent Hospital Memorial Fund Inc is a 501(c)(3) and as such, is described as a "Charitable or Religous organization or a private foundation" by the IRS.
For the year ending 12/2018, Montgomery Manor Convalescent Hospital Memorial Fund Inc generated $454.3k in total revenue. This represents relatively stable growth, over the past 2 years the organization has increased revenue by an average of 0.4% each year. All expenses for the organization totaled $523.0k during the year ending 12/2018. You can explore the organizations financials more deeply in the financial statements section below.
Form
990
Mission & Program ActivityExcerpts From the 990 Filing
TAX YEAR
2018
Describe the Organization's Mission:
Part 3 - Line 1
RESEARCH, EDUCATION AND SUPPORT FOR VICTIMS OF ALZHEIMER'S, THEIR FAMILIES, CAREGIVERS AND THE PUBLIC
Describe the Organization's Program Activity:
Part 3 - Line 4a
BIOGEN: EMERGE STUDY - TO STUDY THE EFFICACY AND SAFETY OF AN INVESTGATIONAL MEDICATION CALLED ADUCANMAB IN PEOPLE EXPERIENCING SYMPTOMS OF EARLY ALZHEIMER'S DISEASE. IT IS THOUGHT THAT ADUCANUMAB RECOGNIZDED HARMFUL AMYLOID PLAQUES FOUND IN THE BRAIN OF PEOPLE WITH ALZHEIMER'S DISEASE. THE STUDY WILL DETERMINE IF THE INVESTIGATIONAL MEDICATION CAN REMOVE THE PLAQUES AND SLOW THE PROGRESSION OF THE DISEASE.
ROCHE - CREAD CRENEZUMAB PROTOCOL - THIS IS A PHASE III RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED SUDY TO EVALUATE THE SAFETY AND EFFICACY OF CRENEZUMAB (A FULLY HUMANIZED MONOCLONAL ANTIBODY) IN PATIENTS WITH INITIAL TO MILD ALZHEIMER'S DISEASE. THE STUDY INVOLVES BIWEEKLY INFUSIONS OF THE DRUG TO ASCERTAIN ANY CHANGE IN THEIR DISEASE SYSTEMS.
LILLY - NAVIGATE - AD STUDY - PARTICIPATED IN AN INTERNATIONAL INVESTGATIONAL DRUG STUDY TO DETERMINE THE POSSIBLE EFFECT OF THE STUDY DRUG ON THE PROTEIN "TAU" BUILD-UP INSIDE THE BRAIN. THE STUDY INVOLVES ORAL DOSING OF PATIENT OVER A PERIOD OF 52 WEEKS WITH A FOLLOW-UP PERIOD TO DETERMINE ANY EFFECT ON THE BUILDUP OF TAU AND OTHER RELATED ALZHEIMER'S SYMPTOMS. THE STUDY ALSO RECORDS AND UNWANTED SIDE EFFECTS.
Get More from Intellispect for FreeCreate a free account to get more data, nonprofit salaries, advanced search and more.
PDF Copies of 990 Filings
Board, Officers & Key Employees
| Name (title) | Role | Hours | Compensation |
|---|---|---|---|
John J Wotring Treasurer | OfficerTrustee | 1 | $0 |
John L Wotring President | OfficerTrustee | 1 | $0 |
Monika Moseley Director | Trustee | 1 | $0 |
Financial Statements
| Statement of Revenue | |
|---|---|
| Federated campaigns | $0 |
| Membership dues | $0 |
| Fundraising events | $0 |
| Related organizations | $0 |
| Government grants | $0 |
| All other contributions, gifts, grants, and similar amounts not included above | $9,608 |
| Noncash contributions included in lines 1a–1f | $0 |
| Total Revenue from Contributions, Gifts, Grants & Similar | $9,608 |
| Total Program Service Revenue | $444,640 |
| Investment income | $38 |
| Tax Exempt Bond Proceeds | $0 |
| Royalties | $0 |
| Net Rental Income | $0 |
| Net Gain/Loss on Asset Sales | $0 |
| Net Income from Fundraising Events | $0 |
| Net Income from Gaming Activities | $0 |
| Net Income from Sales of Inventory | $0 |
| Miscellaneous Revenue | $0 |
| Total Revenue | $454,286 |
| Statement of Expenses | |
|---|---|
| Grants and other assistance to domestic organizations and domestic governments. | $125,924 |
| Grants and other assistance to domestic individuals. | $7,500 |
| Grants and other assistance to Foreign Orgs/Individuals | $0 |
| Benefits paid to or for members | $0 |
| Compensation of current officers, directors, key employees. | $0 |
| Compensation of current officers, directors, key employees. | $0 |
| Compensation to disqualified persons | $0 |
| Other salaries and wages | $97,101 |
| Pension plan accruals and contributions | $0 |
| Other employee benefits | $1,800 |
| Payroll taxes | $8,885 |
| Fees for services: Management | $63,300 |
| Fees for services: Legal | $0 |
| Fees for services: Accounting | $290 |
| Fees for services: Lobbying | $0 |
| Fees for services: Fundraising | $0 |
| Fees for services: Investment Management | $0 |
| Fees for services: Other | $0 |
| Advertising and promotion | $0 |
| Office expenses | $42,869 |
| Information technology | $0 |
| Royalties | $0 |
| Occupancy | $27,998 |
| Travel | $0 |
| Payments of travel or entertainment expenses for any federal, state, or local public officials | $0 |
| Conferences, conventions, and meetings | $300 |
| Interest | $0 |
| Payments to affiliates | $0 |
| Depreciation, depletion, and amortization | $0 |
| Insurance | $9,621 |
| All other expenses | $12,444 |
| Total functional expenses | $523,002 |
| Balance Sheet | |
|---|---|
| Cash—non-interest-bearing | $25,104 |
| Savings and temporary cash investments | $9,254 |
| Pledges and grants receivable | $0 |
| Accounts receivable, net | $0 |
| Loans from Officers, Directors, or Controlling Persons | $0 |
| Loans from Disqualified Persons | $0 |
| Notes and loans receivable | $0 |
| Inventories for sale or use | $0 |
| Prepaid expenses and deferred charges | $0 |
| Net Land, buildings, and equipment | $0 |
| Investments—publicly traded securities | $0 |
| Investments—other securities | $0 |
| Investments—program-related | $0 |
| Intangible assets | $0 |
| Other assets | $0 |
| Total assets | $34,358 |
| Accounts payable and accrued expenses | $0 |
| Grants payable | $0 |
| Deferred revenue | $0 |
| Tax-exempt bond liabilities | $0 |
| Escrow or custodial account liability | $0 |
| Loans and other payables to any current Officer, Director, or Controlling Person | $0 |
| Secured mortgages and notes payable | $0 |
| Unsecured mortgages and notes payable | $0 |
| Other liabilities | $0 |
| Total liabilities | $0 |
| Unrestricted restricted net Assets | $0 |
| Temporarily restricted net Assets | $0 |
| Permanently restricted net Assets or current funds | $0 |
| Capital stock or trust principal, or current funds | $0 |
| Paid-in or capital surplus, or land, building, or equipment fund | $0 |
| Total net assets or fund balances | $34,358 |